{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:03:08Z","timestamp":1740106988603,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00520-022-07159-3","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T04:03:01Z","timestamp":1653105781000},"page":"7271-7280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment"],"prefix":"10.1007","volume":"30","author":[{"given":"Priscila Nunes Costa","family":"Travassos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1513-9027","authenticated-orcid":false,"given":"Paulo Goberl\u00e2nio","family":"de Barros Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena Oliveira","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus Davis Machado","family":"Braga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Barroso","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9ssica Karen","family":"de Oliveira Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Pitombeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline Holanda","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula Negreiros Nunes","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"7159_CR1","unstructured":"Instituto Nacional do C\u00e2ncer (2012). ABC do c\u00e2ncer: abordagens b\u00e1sicas para o controle do c\u00e2ncer. Rev e Atual 1:1\u2013134"},{"key":"7159_CR2","unstructured":"Devita JR VT, Lawrence TL, Rosenberg SA (2011). DeVita, Hellman and Rosenberg's cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins 9:1\u2013384"},{"key":"7159_CR3","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1053\/j.ajkd.2015.04.042","volume":"66","author":"EP Cohen","year":"2015","unstructured":"Cohen EP, Krzesinski JM, Launay-Vacher V (2015) Onco-nephrology: core curriculum 2015. Am J Kidney Dis 66:869\u2013883","journal-title":"Am J Kidney Dis"},{"key":"7159_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/cam4.403","volume":"4","author":"J Arellano","year":"2015","unstructured":"Arellano J, Hernandez RK, Wade SW (2015) Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States. Cancer Med 4:713\u2013720","journal-title":"Cancer Med"},{"key":"7159_CR5","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1002\/cncr.25306","volume":"116","author":"A Lahoti","year":"2010","unstructured":"Lahoti A, Kantarjian H, Slahudeen AK et al (2010) Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 116:4063\u20134068","journal-title":"Cancer"},{"key":"7159_CR6","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A et al (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976\u20134984","journal-title":"J Clin Oncol"},{"key":"7159_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","volume":"22","author":"CF Christiansen","year":"2011","unstructured":"Christiansen CF, Johansen MB, Langeberg WL et al (2011) Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study. Eur J Intern Med 22:399\u2013406","journal-title":"Eur J Intern Med"},{"key":"7159_CR8","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.2215\/CJN.12231212","volume":"8","author":"EC Heher","year":"2013","unstructured":"Heher EC, Rennke HG, Laubach JP et al (2013) Kidney disease and multiple myeloma. Clin J Am Soc Nephrol 8:2007\u20132017","journal-title":"Clin J Am Soc Nephrol"},{"key":"7159_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2215\/CJN.02730313","volume":"9","author":"X Zeng","year":"2014","unstructured":"Zeng X, McMahon GM, Brunelli SM et al (2014) Incidence, outcomes, and comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol 9:12\u201320","journal-title":"Clin J Am Soc Nephrol"},{"key":"7159_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.enfi.2013.01.004","volume":"24","author":"MR Garcia","year":"2013","unstructured":"Garcia MR, Ariza LC, Hito PD (2013) Actualizaci\u00f3n en t\u00e9cnicas continuas de reemplazo renal. Enferm Intensiva 24:113\u2013119","journal-title":"Enferm Intensiva"},{"key":"7159_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/MCC.0b013e32830ef70b","volume":"14","author":"N Lameire","year":"2008","unstructured":"Lameire N, Van BW, Vanholder R (2008) Acute renal problems in the critically ill cancer patient. Curr Opin Crit Care 14:635\u2013646","journal-title":"Curr Opin Crit Care"},{"key":"7159_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/ckj\/sfw026","volume":"9","author":"T Chuva","year":"2016","unstructured":"Chuva T, Maximino J, Barbosa J et al (2016) Haematological malignancies and acute kidney injury requiring nephrology consultation: challenging the worst of the worst. Clin Kidney J 9:418\u2013423","journal-title":"Clin Kidney J"},{"key":"7159_CR13","doi-asserted-by":"publisher","first-page":"m2687","DOI":"10.1136\/bmj.m2687","volume":"370","author":"DA Simonetto","year":"2020","unstructured":"Simonetto DA, Gines P, Kamath PS (2020) Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ 370:m2687","journal-title":"BMJ"},{"key":"7159_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/j.ajkd.2013.02.349","volume":"61","author":"PM Palevsky","year":"2013","unstructured":"Palevsky PM, Liu KD, Brophy PD et al (2013) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 61:1\u2013141","journal-title":"Am J Kidney Dis"},{"key":"7159_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ejim.2014.06.023","volume":"25","author":"L Rodrigues","year":"2014","unstructured":"Rodrigues L, Neves M, S\u00e1 H et al (2014) Severe acute kidney injury and multiple myeloma: evaluation of kidney and patient prognostic factors. Eur J Intern Med 25:652\u2013656","journal-title":"Eur J Intern Med"},{"key":"7159_CR16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.semnephrol.2010.09.005","volume":"30","author":"MA Perazella","year":"2010","unstructured":"Perazella MA, Moeckel GW (2010) Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention\/therapy. Semin Nephrol 30:570\u2013581","journal-title":"Semin Nephrol"},{"key":"7159_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.02780312","volume":"7","author":"MA Perazella","year":"2012","unstructured":"Perazella MA (2012) Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 7:1713\u20131721","journal-title":"Clin J Am Soc Nephrol"},{"key":"7159_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"key":"7159_CR19","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.3324\/haematol.2016.150706","volume":"102","author":"P Strati","year":"2017","unstructured":"Strati P, Chaffe KG, Achenbach SJ et al (2017) Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leucemia. Haematologica 102:e22\u2013e25","journal-title":"Haematologica"},{"key":"7159_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1590\/S1516-84842009005000013","volume":"31","author":"ROP Silva","year":"2009","unstructured":"Silva ROP, Brand\u00e3o KMA, Pinto PVM et al (2009) Multiple myeloma: clinical and laboratory characteristics in the diagnosis and prognostic study. Rev Bras Hematol Hemoter 31:63\u201368","journal-title":"Rev Bras Hematol Hemoter"},{"key":"7159_CR21","first-page":"216","volume":"8","author":"TM Sakae","year":"2012","unstructured":"Sakae TM, Santos NAF, Baldessar MZ (2012) Sobrevida de pacientes portadores de mieloma m\u00faltiplo atendidos em hospital de refer\u00eancia no Sul de Santa Catarina. Rev Bras Clin Med 8:216\u2013221","journal-title":"Rev Bras Clin Med"},{"key":"7159_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.17696\/2318-3691.25.1.2018.927","volume":"25","author":"AAC Furini","year":"2018","unstructured":"Furini AAC, Alves MC, Madeira EB et al (2018) Perfil de pacientes com diagn\u00f3stico patol\u00f3gico de mieloma m\u00faltiplo em hospital de ensino. Arq Ci\u00eanc Sa\u00fade 25:61\u201364","journal-title":"Arq Ci\u00eanc Sa\u00fade"},{"key":"7159_CR23","first-page":"86","volume":"29","author":"A Maiolino","year":"2007","unstructured":"Maiolino A, Magalh\u00e3es RJP (2007) Mieloma m\u00faltiplo e insufici\u00eancia renal. Rev Bras Hematol e Hemot 29:86\u201391","journal-title":"Rev Bras Hematol e Hemot"},{"key":"7159_CR24","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/cam4.1075","volume":"6","author":"Y Quian","year":"2017","unstructured":"Quian Y, Bhowmik D, Bond C et al (2017) Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States. Cancer Med 6:1523\u20131530","journal-title":"Cancer Med"},{"key":"7159_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.32635\/2176-9745.RBC.2010v56n4.1464","volume":"56","author":"JSM Rodrigues","year":"2010","unstructured":"Rodrigues JSM, Ferreira NMLA (2010) Caracteriza\u00e7\u00e3o do perfil epidemiol\u00f3gico do c\u00e2ncer em uma cidade do interior paulista: conhecer para intervir. Rev Bras Cancerol 56:431\u2013441","journal-title":"Rev Bras Cancerol"},{"key":"7159_CR26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1681\/ASN.2010080857","volume":"22","author":"CA Hutchison","year":"2011","unstructured":"Hutchison CA, Cockwell P, Stringer S et al (2011) Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 22:1129\u20131136","journal-title":"J Am Soc Nephrol"},{"key":"7159_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.4103\/0971-4065.158176","volume":"25","author":"FP Tillmann","year":"2015","unstructured":"Tillmann FP (2015) Daily postdilutional hemodiafiltration with FX800 polysulfone dialyzers for removing kappa light chains in multiple myeloma-induced kidney injury. Indian J Nephrol 25:237\u2013341","journal-title":"Indian J Nephrol"},{"key":"7159_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2298\/VSP140210027R","volume":"72","author":"V Rabrenovic","year":"2015","unstructured":"Rabrenovic V, Miju\u0161kovi\u0107 Z, Marjanovi\u0107 S et al (2015) Kidney failure as an unusual initial presentation of biclonal gammopathy IgD multiple myelomaassociated with light chain disease. \u2013a case report. Vojnosanit Pregl 72:196\u2013199","journal-title":"Vojnosanit Pregl"},{"key":"7159_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ndt\/gfv283","volume":"31","author":"L Ecoti\u00e9rel","year":"2016","unstructured":"Ecoti\u00e9rel L, Thierry A, Debiais-Delpech C et al (2016) Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant 31:64\u201372","journal-title":"Nephrol Dial Transplant"},{"key":"7159_CR30","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1177\/0883073813491829","volume":"29","author":"P Jain","year":"2014","unstructured":"Jain P, Gulati S, Seth R et al (2014) Vincristine-induced neuropathy in childhood all (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics. J Child Neurol 29:932\u2013937","journal-title":"J Child Neurol"},{"key":"7159_CR31","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1017\/S0317167100018461","volume":"41","author":"MJ Purser","year":"2014","unstructured":"Purser MJ, Johnston DL (2014) Chemotherapy-induced peripheral neuropathy among paediatric oncology patients. Can J Neurol Sci 41:442\u2013447","journal-title":"Can J Neurol Sci"},{"key":"7159_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jcrc.2016.06.007","volume":"36","author":"K Leeuw","year":"2016","unstructured":"Leeuw K, Niemeijer AS, Eshuis J et al (2016) Effect and mechanism of hydrocortisone on organ function in patients with severe burns. J Crit Care 36:200\u2013206","journal-title":"J Crit Care"},{"key":"7159_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CCM.0000000000002255","volume":"45","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45:486\u2013552","journal-title":"Crit Care Med"},{"key":"7159_CR34","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.chest.2017.07.014","volume":"152","author":"N Barabutis","year":"2017","unstructured":"Barabutis N, Barabutis N, Khangoora V et al (2017) Hydrocortisone and ascorbic acid synergistically prevent and repair lipopolysaccharide-induced pulmonary endothelial barrier dysfunction. Chest 152:954\u2013962","journal-title":"Chest"},{"key":"7159_CR35","first-page":"2366","volume":"6","author":"J Zhang","year":"2013","unstructured":"Zhang J, Yao Y, Ciao F et al (2013) Administration of dexamethasone protects mice against ischemia\/reperfusion induced renal injury by suppressing PI3K\/AKT signaling. Int J Clin Exp Pathol 6:2366\u20132375","journal-title":"Int J Clin Exp Pathol"},{"key":"7159_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1631\/jzus.B1900006","volume":"20","author":"W Yu","year":"2019","unstructured":"Yu W, Zhang S, Fu S et al (2019) Dexamethasone protects the glycocalyx on the kidney microvascular endothelium during severe acute pancreatitis. J Zhejiang Univ-Sci B (Biomed & Biotechnol) 20:355\u2013362","journal-title":"J Zhejiang Univ-Sci B (Biomed & Biotechnol)"},{"key":"7159_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.canlet.2015.10.002","volume":"369","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Yu X, Wang Z et al (2015) Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy. Cancer Lett 369:331\u2013335","journal-title":"Cancer Lett"},{"key":"7159_CR38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neuro.2016.09.010","volume":"57","author":"P Ben","year":"2016","unstructured":"Ben P, Ben P, Zhang Z et al (2016) LuoL-Theanine attenuates cadmium-induced neurotoxicity through the inhibition of oxidative damage and tau hyperphosphorylation. Neurotoxicology 57:95\u2013103","journal-title":"Neurotoxicology"},{"key":"7159_CR39","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","volume":"85","author":"RA Larson","year":"1995","unstructured":"Larson RA, Dodge RK, Burns CP et al (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85:2025\u20132037","journal-title":"Blood"},{"key":"7159_CR40","first-page":"471","volume":"12","author":"T Mujtaba","year":"2011","unstructured":"Mujtaba T, Dou QP (2011) Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 12:471\u2013480","journal-title":"Discov Med"},{"key":"7159_CR41","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.bbmt.2013.05.011","volume":"19","author":"M Mohty","year":"2013","unstructured":"Mohty M, Brissot E, Savani BN (2013) Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 19:1416\u20131420","journal-title":"Biol Blood Marrow Transplant"},{"key":"7159_CR42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4103\/sajc.sajc_59_17","volume":"7","author":"MSH Zafar","year":"2018","unstructured":"Zafar MSH, Khan AA, Aggarwal S et al (2018) Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma. South Asian J Cancer 7:58\u201360","journal-title":"South Asian J Cancer"},{"key":"7159_CR43","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","volume":"109","author":"AA Chanan-khan","year":"2007","unstructured":"Chanan-khan AA, Kaufman JL, Mehta J et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604\u20132606","journal-title":"Blood"},{"key":"7159_CR44","first-page":"e01293","volume":"61","author":"N Finch","year":"2017","unstructured":"Finch N, Zasowski E, Murray K, Mynatt R, Zhao J, Yost R et al (2017) A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Clin Therap 61:e01293-e1317","journal-title":"Clin Therap"},{"key":"7159_CR45","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00280-020-04147-4","volume":"86","author":"T Morita-Ogawa","year":"2020","unstructured":"Morita-Ogawa T, Sugita H, Minami H, Yamaguchi T, Hanada K (2020) Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction. Cancer Chem Pharm 86:559\u2013566","journal-title":"Cancer Chem Pharm"},{"key":"7159_CR46","doi-asserted-by":"publisher","first-page":"e16311","DOI":"10.1097\/MD.0000000000016311","volume":"98","author":"TC Lin","year":"2019","unstructured":"Lin TC, Hunh L, Chen YC, Lo WC et al (2019) Effects of febuxostat on renal function in patients with chronic kidney disease. Med 98:e16311","journal-title":"Med"},{"key":"7159_CR47","first-page":"4075","volume":"37","author":"I Arany","year":"2017","unstructured":"Arany I, Hall S, Faisal A et al (2017) Nicotine exposure augments renal toxicity of 5-aza-cytidine through p66shc: prevention by resveratrol. Anticancer Res 37:4075\u20134079","journal-title":"Anticancer Res"},{"key":"7159_CR48","first-page":"84","volume":"1","author":"MPR Sanchez","year":"2016","unstructured":"Sanchez MPR, Pereira R, Nogeuir LM et al (2016) Dental implants in patients with bone metabolic diseases under bisphosphonate therapy \u00ad a literature review. INPerio 1:84\u201394","journal-title":"INPerio"},{"key":"7159_CR49","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1124\/dmd.108.021071","volume":"36","author":"HM Weiss","year":"2008","unstructured":"Weiss HM, Pfaar U, Schweitzer A et al (2008) Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 36:2043\u20132049","journal-title":"Drug Metab Dispos"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07159-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07159-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T20:08:00Z","timestamp":1666728480000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07159-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["7159"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07159-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"5 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research is in accordance with ethical principles, and the Ethics Committee for Research on Human Beings of the Faculty of Medicine (UFC) was firstly approved with CAAE 87952818.7.0000.5054 and then by the Ethics Committee of the Walter Cant\u00eddeo University Hospital (UFC) under CAAE number 87952818.7.3001.5045.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors are aware of the possible publication and everyone agrees with it.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}